Abstract: Disclosed is an online optimization method for a power consumption policy of a terminal of Internet of things (IoT), including: performing comprehensive scanning on a user terminal and a link, and obtaining a link behavior graph; inputting the link behavior graph into a simulation based optimization (SBO) system to obtain power consumption parameters for minimizing power consumption of the user terminal; performing centralized storage on the link behavior graph and the power consumption parameters; regularly sending, by the user terminal, operation data to a server, and evaluating, by the server, whether a power consumption policy needs to be optimized; and issuing, by the server, a parameter update instruction to complete the upgrading of the power consumption policy of the user terminal. In the present disclosure, the update of the power consumption policy of the user terminal can be conveyed more quickly and more efficiently.

Abstract: An antigen-binding molecule specifically binding to HGFR and EGFR, and the pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.

Abstract: The invention provides an anti-C5 humanized monoclonal antibody with low immunogenicity and low ADCC/CDC function and its application. By modifying the amino acid sequence of the framework region of Eculizumab monoclonal antibody, the immunogenicity was reduced, and the antibody was replaced from IgG2 subtype to IgG1 subtype, and a flexible amino acid sequence was inserted between the CDR3 and CH2 regions of the heavy chain of the IgG1 antibody to reduce the immunogenicity. The purpose of ADCC/CDC function is to improve the stability of the antibody and prolong its half-life. The binding affinity of the monoclonal antibody of the invention to human C5 is similar to that of the original Eculizumab antibody, it can specifically block the complement hemolytic activity of C5 and the production of C5a and can be used for the preparation of C5-targeted paroxysmal nocturnal hemoglobinuria and atypical the drug for the treatment of hemolytic uremic syndrome has excellent clinical therapeutic value.

Abstract: A backlight and a display device are provided herein, which is related to the field of display technology and intends to improve visual effect of the image displayed by the display device. The backlight may include a back plate, a light guide plate and a light source. The back plate includes an accommodation groove, and the light guide plate includes a holding groove at a first side surface of the light guide plate. The light source includes at least one light emitting element. The holding groove is configured to hold at least a portion of the at least one light emitting element, and the accommodation groove is configured to accommodate the light guide plate and the light source.

Abstract: The present invention relates to an anti-CD70 antibody and an application thereof. Specifically, the present disclosure relates to an anti-CD70 antibody, which comprises a light chain variable region and a heavy chain variable region of the antibody, and a use as a drug.

Abstract: Provided is an anti-TNF-? humanized monoclonal antibody, TCX060, wherein the antibody is obtained by means of modifying Certolizumab as follows: (1) removing PEG modification; (2) transforming same into a full-length antibody of a human IgG1 subtype; and (3) inserting a flexible amino acid fragment between CDR3 and CH2 regions.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: A backlight and a display device are provided herein, which is related to the field of display technology and intends to improve visual effect of the image displayed by the display device. The backlight may include a back plate, a light guide plate and a light source. The back plate includes an accommodation groove, and the light guide plate includes a holding groove at a first side surface of the light guide plate. The light source includes at least one light emitting element. The holding groove is configured to hold at least a portion of the at least one light emitting element, and the accommodation groove is configured to accommodate the light guide plate and the light source.

Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of a humanized anti-DKK2 antibody, methods for providing anti-tumor immunity in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.

Abstract: The present application provides an anti-CD38 antibody, an antigen-binding fragment thereof, and pharmaceutical use. Specifically, the present application provides a murine-derived antibody, a chimeric antibody or a humanized antibody comprising a CDR region of the anti-CD38 antibdoy, a pharmaceutical composition comprising the anti-CD38 antibody or the antigen-binding fragment thereof, and an application thereof as a drug. In particular, the present application provides an application of a humanized anti-CD38 antibody in preparing a drug for treating a CD38 positive disease or disorder.

Abstract: A display panel and a manufacture method thereof, and a display apparatus are provided. The display panel includes a first substrate and a second substrate which arranged opposite to each other. The first substrate includes a display region and a peripheral region, a conduction section is in the peripheral region of the first substrate, and the conduction section is electrically connected with a grounded section. The second substrate includes a display region and a peripheral region, a black matrix is at least in the peripheral region of the second substrate, and the black matrix is electrically connected with the conduction section.

Abstract: The present disclosure is related to a display panel. The display panel may include a first light shielding layer (101) in a display region and a second light shielding layer (212) opposite the first light shielding layer (101) in the display region. The first light shielding layer (101) may include a plurality of first openings (112), and the second light shielding layer (212) may include a plurality of second openings (222). The display region may include a middle display region (20A) and a periphery display region (20B). An area of each of the plurality of the first openings (112) in the periphery display region (20B) may be smaller than an area of each of the plurality of the first openings (112) in the middle display region (20A).

Abstract: The present invention provides De-ADCC/CDC activity monoclonal antibodies and their generation method and applications. The present invention modified the antibody sequences of multi-target sites such as PD-L1, PD-1, CTLA4, TNF-?, PCSK9, NGF, CD47 and C5. A flexible amino acid sequence was inserted between the heavy chain CDR3 and CH2 regions of IgG1 antibody to block the physical stress signal transmit from antigen-bound Fab to its Fc region to reduce the ADCC/CDC activity while not significantly increasing the formation of the polymers. The modified antibodies in the present invention and the original antibodies target the same sites, but the antibody subtype or glycosylation state is different. For the modified antibodies in the present invention, the stability is significantly improved or/and immunogenicity is significantly reduced, and the half-life is prolonged. The modified antibodies eliminate the activity of ADCC/CDC.

Abstract: The present disclosure is related to a display panel. The display panel may include a first light shielding layer (101) in a display region and a second light shielding layer (212) opposite the first light shielding layer (101) in the display region. The first light shielding layer (101) may include a plurality of first openings (112), and the second light shielding layer (212) may include a plurality of second openings (222). The display region may include a middle display region (20A) and a periphery display region (20B). An area of each of the plurality of the first openings (112) in the periphery display region (20B) may be smaller than an area of each of the plurality of the first openings (112) in the middle display region (20A).

Abstract: The present disclosure provides an array substrate and a manufacturing method thereof, a liquid crystal display panel, and a liquid crystal display apparatus, which can solve a problem that an independent backlight of the related liquid crystal display device is easy to cause light leakage, resulting in a thicker product. Both a light emitting structure and an array structure are disposed on the array substrate of the present disclosure, wherein a control device of the light emitting structure can control the light emitting source to emit light. That is, in the present disclosure, the light emitting structure is directly formed in the array substrate, which is equivalent to a built-in light emitting source, so that it is no longer necessary to adhere an external backlight, and no adhesive gap is generated to cause light leakage, and the thickness of the product can be reduced.

Abstract: A method for treating autoimmune and inflammatory diseases in a human includes administering an effective amount of a low immunogenic human anti-TNF-? antibody to the human, thereby targeting TNF-?. The low immunogenic human anti-TNF-? antibody includes CDR regions of heavy and light chains from human Adalimumab, and also includes an additional human light chain amino acid sequence, and an additional human heavy chain amino acid sequence. The antibody has reduced immunogenicity compared to Adalimumab.

Abstract: A display panel and a manufacture method thereof, and a display apparatus are provided. The display panel includes a first substrate and a second substrate which arranged opposite to each other. The first substrate includes a display region and a peripheral region, a conduction section is in the peripheral region of the first substrate, and the conduction section is electrically connected with a grounded section. The second substrate includes a display region and a peripheral region, a black matrix is at least in the peripheral region of the second substrate, and the black matrix is electrically connected with the conduction section.

Abstract: The disclosure provides an array substrate, a display device, a detecting apparatus and a detecting method for detecting a defect connection of a data line. A data signal input bus of the array substrate of the present disclosure applies a data signal to each pixel unit, and a detection line is added on one side of the array substrate opposite to the data signal input bus, when the product is detected, the data signal input bus inputs the normal data signal, the detection line on the other side inputs a signal having a polarity contrary to that of the data signal. At a position of the data line existing defect connection, heat is generated and the data line is burnt at the position existing defect connection.

Abstract: Disclosed herein are low immunogenic human anti-TNF-?antibodies which can inhibit the apopotosis of cells induced by TNF-?. The invented low immunogenic human anti-TNF-? antibodies are capable of binding to TNF-? specifically. The invention presents the human anti-TNF-?antibodies which bind to TNF-? with similar affinities as Adalimumab. Most importantly, the invented human anti-TNF-? antibodies showed reduced immunogenicities in vivo, which made them safer candidate for antibody drug and other biotherapy. The invention also features method of de-immunogenicity of antibody drugs by identification, replacement of high immunogenic FR sequence(s) of the human antibody with low immunogenic FR sequences from other human IgGs, and significantly reduce the risk of human anti-human immunogenicity and improve the efficacy of antibody drugs.

Abstract: The embodiments of the present application provide a detection method and a detection device. The detection device includes: a capacitance generation circuit comprising a first capacitance electrode and a second capacitance electrode disposed opposite to each other, and a power source coupled to the first and the second capacitance electrode, the first capacitance electrode is an electrode plate, and the second capacitance electrode comprises n sub-electrodes which are provided to be insulated from each other; at least one capacitance detection circuit coupled to the electrode plate and the sub-electrodes, and configured to detect a capacitance value between the electrode plate and the sub-electrodes in response to a substrate to be tested being placed on one side of the electrode plate; and a controller configured to determine, according to the detected capacitance value, whether a foreign object exists in a region on the substrate to be tested or not.